Benzinga | Aug 4, 2021 08:57AM EDT

Clovis Oncology Earlier Reported Q2 Adj. EPS $(0.59) Misses $(0.56) Estimate, Sales $36.82M Miss $41.12M Estimate

Clovis Oncology (NASDAQ:CLVS) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of $(0.56) by 5.36 percent. This is a 46.85 percent increase over losses of $(1.11) per share from the same period last year. The company reported quarterly sales of $36.82 million which missed the analyst consensus estimate of $41.12 million by 10.46 percent. This is a 7.69 percent decrease over sales of $39.89 million the same period last year.